"Better Diet Quality and Decreased Mortality Among Myocardial Infarction Survivors"
JAMA IM
http://archinte.jamanetwork.com/article.aspx?articleid=1733453
"Conclusions and Relevance Myocardial infarction survivors who consume a higher-quality diet, which has been associated with a lower risk of coronary heart disease in primary prevention, have lower subsequent all-cause mortality."
Friday, November 8, 2013
Thursday, November 7, 2013
"Low Levels of High-Density Lipoprotein Cholesterol and Increased Risk of Cardiovascular Events in Stable Ischemic Heart Disease Patients"
JACC
http://content.onlinejacc.org/article.aspx?articleid=1731137
"Conclusions In this post-hoc analysis, patients with SIHD continued to experience incremental cardiovascular risk associated with low HDL-C levels despite OMT during long-term follow-up. This relationship persisted and appeared more prominent even when LDL-C was reduced to optimal levels with intensive dyslipidemic therapy."
JACC
http://content.onlinejacc.org/article.aspx?articleid=1731137
"Conclusions In this post-hoc analysis, patients with SIHD continued to experience incremental cardiovascular risk associated with low HDL-C levels despite OMT during long-term follow-up. This relationship persisted and appeared more prominent even when LDL-C was reduced to optimal levels with intensive dyslipidemic therapy."
Wednesday, November 6, 2013
"Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR):
an open-label, randomised, phase 2 trial"
Lancet
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)62121-2/fulltext
"Interpretation
an open-label, randomised, phase 2 trial"
Lancet
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)62121-2/fulltext
"Interpretation
These findings suggest that the fixed-dose combination of sofosbuvir-ledipasvir alone or with ribavirin has the potential to cure most patients with genotype-1 HCV, irrespective of treatment history or the presence of compensated cirrhosis. Further clinical trials are needed to establish the best treatment duration and to further assess the contribution of ribavirin."
Tuesday, November 5, 2013
"Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma"
NEJM
"CONCLUSIONS
NEJM
"CONCLUSIONS
Early autologous stem-cell transplantation improved progression-free survival among patients with high-intermediate-risk or high-risk disease who had a response to induction therapy. Overall survival after transplantation was not improved, probably because of the effectiveness of salvage transplantation."
http://www.nejm.org/doi/full/10.1056/NEJMoa1301077
http://www.nejm.org/doi/full/10.1056/NEJMoa1301077
Monday, November 4, 2013
"Effect of Statin Therapy on Mortality in Patients With Ventilator-Associated Pneumonia"
JAMA Oct 23/30
http://jama.jamanetwork.com/article.aspx?articleid=1752244
"Conclusions and Relevance In adults with suspected VAP, adjunctive simvastatin therapy compared with placebo did not improve day-28 survival. These findings do not support the use of statins with the goal of improving VAP outcomes."
JAMA Oct 23/30
http://jama.jamanetwork.com/article.aspx?articleid=1752244
"Conclusions and Relevance In adults with suspected VAP, adjunctive simvastatin therapy compared with placebo did not improve day-28 survival. These findings do not support the use of statins with the goal of improving VAP outcomes."
Saturday, November 2, 2013
Weekly Guideline
"Screening, Monitoring, and Treatment of Stage 1 to 3 Chronic Kidney Disease"
Annals Oct 2013
http://annals.org/article.aspx?articleid=1757302
Annals Oct 2013
http://annals.org/article.aspx?articleid=1757302
Friday, November 1, 2013
"A 2-Hour Diagnostic Protocol for Possible Cardiac Chest Pain in the Emergency Department"
JAMA IM Nov 1
http://archinte.jamanetwork.com/article.aspx?articleid=1748796
"Conclusions and Relevance Using the accelerated diagnostic protocol in the experimental pathway almost doubled the proportion of patients with chest pain discharged early. Clinicians could discharge approximately 1 of 5 patients with chest pain to outpatient follow-up monitoring in less than 6 hours. This diagnostic strategy could be easily replicated in other centers because no extra resources are required."
JAMA IM Nov 1
http://archinte.jamanetwork.com/article.aspx?articleid=1748796
"Conclusions and Relevance Using the accelerated diagnostic protocol in the experimental pathway almost doubled the proportion of patients with chest pain discharged early. Clinicians could discharge approximately 1 of 5 patients with chest pain to outpatient follow-up monitoring in less than 6 hours. This diagnostic strategy could be easily replicated in other centers because no extra resources are required."
Subscribe to:
Posts (Atom)